key: cord-0779517-9nyuri8m
authors: Shihong Gao, David; Zhu, Xiaodong; Lu, Binfeng
title: Development and application of sensitive, specific, and rapid CRISPR‐Cas13‐based diagnosis
date: 2021-03-25
journal: J Med Virol
DOI: 10.1002/jmv.26889
sha: 371881546b9baa7ba744dc8b042205c990aaf93e
doc_id: 779517
cord_uid: 9nyuri8m

Nucleic acid detection is a necessary part of medical treatment and fieldwork. However, the current detection technologies are far from ideal. A lack of timely and accessible testing for identifying cases and close contacts has allowed severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), the causative virus of the ongoing coronavirus disease‐2019 (COVID‐19) pandemic, to spread uncontrollably. The slow and expensive detection of mutations—predictors for chronic diseases such as cancer—form a barrier to personalized treatment. A recently developed diagnostic assay is ideal and field‐ready—it relies on CRISPR‐Cas13. CRISPR‐Cas13 works similarly to other CRISPR systems: Cas13 is guided by a crRNA to cleave next to a specific RNA target sequence. Additionally, Cas13 boasts a unique collateral cleavage activity; collateral cleavage of a fluorescent reporter detects the presence of the target sequence in sample RNA. This system forms the basis of CRISPR‐Cas13 diagnostic assays. CRISPR‐Cas13 assays have >95% sensitivity and >99% specificity. Detection is rapid (<2 h), inexpensive ($0.05 per test), and portable—a test using lateral flow strips is akin to a pregnancy test. The recent adaptation of micro‐well chips facilitates high‐level multiplexing and is high‐throughput. In this review, we cover the development of CRISPR‐Cas13 assays for medical diagnosis, discuss the advantages of CRISPR‐Cas13‐based diagnosis over the traditional reverse transcription polymerase chain reaction (RT‐PCR), and present examples of detection from real patient samples.

Diagnostics are a necessary part of medical treatment and field work. One approach to diagnostics is the detection of nucleic acids. In particular, the detection of pathogen DNA or RNA in patient samples, such as by reverse transcription polymerase chain reaction (RT-PCR) tests, informs if a patient is infected. 1 The COVID-19 pandemic proves that nucleic acid detection is urgently needed to control the spread of emerging and remerging pathogens. Recent pandemics were caused by the related coronaviruses Middle East respiratory syndrome-related coronavirus (MERS, 2012) and severe acute respiratory syndrome coronavirus-1 (SARS-CoV- 1, 2003) , as well as the H1N1 strain of influenza A virus (IAV, 2009). 4, 5 Nucleic acid detection is also needed to personalize treatment against chronic diseases. In the case of HIV, the virus can acquire many types of drug-resistant mutations that affect various drugs. As a result, patients must be tested for mutations by the individual so that each patient can have their drug regimen adjusted to their specific mutation. 6 Humans also naturally develop nucleotide polymorphisms (SNPs). SNPs require personalized detection and treatment-they are unique to each patient's DNA. SNPs serve as predictors for cancer and also tell which immunotherapy is an effective treatment. 7, 8 In addition, SNPs tell which immunosuppressant is an effective treatment for autoimmune diseases or after organ transplanations. 9 Detection of mutations is most commonly performed by highthroughput sequencing of DNA or RNA. 10 The benefit of highthroughput sequencing is that the technology provides genome-wide information. However, sequencing the entire genome costs thousands of dollars per patient, and sequencing large amounts of information means that the required equipment is complex and not available at all treatment centers. 10 Detection for mutations needs to be made more accessible, flexible, and cost-effective so that every patient can benefit from personalized treatment.

While nucleic acid detection tells whether a patient has a disease-related mutation or is infected with a pathogen, it is important to acknowledge that detection is not a complete medical diagnosis. A complete diagnosis also takes into account a patient's condition, such as the stage of viral infection or tumor progression, as well as a patient's symptoms and medical history.

During a pandemic, widespread testing for a pathogen is used without doctor input. However, this strategy is again to help doctors by buying them time to attend to more serious cases, the triage of which still considers symptoms. Along these lines, nucleic acid detection guides the decision-making for a complete diagnosis.

Medical diagnosis covers a wide-range of fields-there are no existing assays that can detect pathogen messenger RNA (mRNA) but also find single-nucleotide mutations out of an entire genome, all while meeting the needs and holding up to the inadequacies of any clinical environment. In the search for a holistic solution, much progress has been made in developing clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) protein 13 as a diagnostic assay. CRISPR-Cas13 diagnostic assays are sensitive, specific, inexpensive, rapid, and portable. CRISPR-Cas13 assays are also field-ready. In this review, we cover the development of CRISPR-Cas13 diagnostic assays for medical diagnosis. We discuss the advantages of CRISPR-Cas13-based diagnosis as compared to The CRISPR-Cas system was first discovered in action with the Cas9 protein, and CRISPR-Cas9 has since been harnessed for genome editing of DNA in vitro and in vivo. 10, 11, 13 Cas9 works in tandem with a gRNA (guide RNA). The gRNA comprises a CRISPR RNA (crRNA) that has its 3ʹ end based paired to a tracrRNA. 14 The free 5ʹ end of the crRNA is a target sequence from DNA. 14 Cas9 grabs onto the tracrRNA, forming a binary complex. This allows Cas9 to guide the crRNA target sequence to the complementary region (protospacer) on a DNA molecule. The pairing of the crRNA to the protospacer will separate the matching second DNA strand and forms the Cas9-gRNA-protospacer ternary complex. Dependent on the presence of the protospacer and a protospacer adjacent motif (PAM), 15 the crRNA target sequence serves as a guide for Cas9 to cleave both DNA strands within the protospacer sequence. 16 For convenience with genome editing, the crRNA and tracrRNA are programmed into a single chimera, called a sgRNA (single guide RNA), where the two molecules are connected by a loop in addition to base pairing. 17 CRISPR-Cas13 is a variant of CRISPR-Cas9 where Cas13 cleaves RNA instead of DNA. 18 CRISPR-Cas12 is works similarly but with DNA; several key differences between CRISPR-Cas12 and Cas13 are summarized in Table 1 . Since this review is focused on RNA detection, here we describe the function of CRISPR-Cas13. The system uses a crRNA that is comprised of a target sequence (spacer) and an adjacent stem-loop, called a direct repeat (DR). 18 Cas13 grabs the DR, and guides the crRNA such that the spacer matches and base pairs with the complementary sequence on sample RNA. 18 In contrast to Cas9, Cas13 then cleaves distal to the RNA target sequence that is paired with a spacer. 18 Cas13 has specific sequence requirements for cleavage. First, cleavage can occur at any distance along with the RNA that is away from the target sequence, though Cas13 cleaves only where the RNA is single-stranded. 18 Second, Cas13 is tolerant to single base pair mismatches in spacer-RNA pairing but not double base pair mismatches. 18 Based on this property, the synthetic addition of a single base pair mismatch in the spacer means that a lack of targeting by Cas13 identifies any additional mutations that occur in the sample nucleic acid. 20, 24, 25 Lastly, Cas13 has specific base preferences for cleavage: most orthologs prefer Us, a combination of bases, though more rarely, As. 20 The target cleavage activities of Cas9 and Cas13 act in cis. Cas13 has an additional trans (collateral) cleavage activity that works on surrounding nontarget ssRNA; collateral cleavage is dependent on target cleavage. 18 Collateral cleavage occurs with specific dinucleotide preferences that vary greatly by Cas13 ortholog. 20 The collateral cleavage activity of Cas13 forms the basis of Cas13 diagnostic assays.

Gootenberg et al. 20 were the first to develop CRISPR-Cas13 as a diagnostic assay. A detection mix is used that consists of sample RNA, Cas13a, designed crRNA, and reporter RNA (RNA sensor) that has a fluorophore and quencher on opposing ends. 20 If sample RNA is present that contains the target sequence, Cas13 will cleave the sample RNA and collaterally cleave the RNA sensor to relieve the fluorophore. 20 Thus, fluorescence is the output of whether the target is present or not. The fluorescence level is quantitative for the amount of target in the sample. 20, [24] [25] [26] 28 This assay is termed specific high-sensitivity enzymatic reporter unlocking (SHERLOCK). 20 The process of SHERLOCK involves two-steps. In the first step, DNA purified from the sample undergoes recombinase polymerase amplification (RPA) (or reverse transcription [RT]-RPA for RNA) and the amplified DNA undergoes T7 RNA polymerase transcription to RNA. In the second step, the resulting amplified RNA is added to the CRISPR-Cas13 target sequence detection reaction. 20 A comprehensive SHERLOCK protocol is published by Kellner et al. 27 

One of the major inconveniences to SHERLOCK is the need to perform initial nucleic acid purification. Early experiments showed that detection without purification only works for synthetic nucleic acids spiked in up to 2% human serum, 18 but these sample conditions are not so favorable in real patient samples. However, modifications to the original protocols have now allowed for direct detection from raw patient samples. One procedure, called heating unextracted diagnostic samples to obliterate nucleases (HUDSON), uses chemical reduction from bench-stable reagents along with heat to inactivate nucleases and virus. 24 Raw patient samples-such as blood, saliva, and urine-are added into one tube for HUDSON and then transferred into a second tube for SHERLOCK. 24 Still, it is cumbersome to use separate tubes for HUDSON and SHERLOCK. A new procedure called STOP (SHERLOCK testing in one pot) accomplishes nucleic acid purification and detection into one tube/pot. 28 The initial extraction is simplified to a single step by using magnetic beads that concentrate RNA. 28 The second set of reagents are added: loop-mediated isothermal amplification (LAMP) makes and amplifies DNA that is detected in a SHERLOCK reaction. 28 The ssDNA-detecting Cas12b is used because the enzyme is heat-stable (Alicyclobacillus acidiphilus; AapCas12b) to survive the LAMP. 20 A similar, also new, procedure, called diagnostics with coronavirus enzymatic reporting (DISCoVER), combines HUDSON with LAMP amplification and T7 RT for detection. 29 Another recent modification that improves the speed and convenience of SHERLOCK is skipping the PCR amplification step. To get SHERLOCK to work with less input, the researchers employed two strategies. First, the researchers chose optimal crRNAs that when tested yielded the highest fluorescence levels. 30 Second, multiple crRNAs were combined into a single reaction so that more Cas13 that can bind to the target and induce more detectable fluorescence. 30 CRISPR-Cas13 has also been improved for multiplexed detection. For separate target specificities, Cas13 orthologs are matched to crRNAs based on their DR base preferences. 25 For separate readouts, the orthologs are also matched to RNA sensors based on their base preferences for collateral cleavages. 25 These strategies allow for one Cas13a ortholog, two Cas13b orthologs, and one Cas12a ortholog (cleaves dsDNA) to be mixed with four crRNAs and four RNA sensors to detect three RNA targets and one DNA target. 25 The problem with this early method of multiplexing is that each Cas13 ortholog only works with one crRNA; the number of multiplexed targets is limited by the number of crRNA-ortholog pairs that can be added to a tube before having molecules stops the detection reaction. Moreover, most orthologs cannot be used together because The latter two studies showed more sensitivity errors-false negatives. Indeed, the errors arise from samples that have low viral load and thus RT-qPCR CTs above 33.5 26 or 37. 28 In fact, optimization of SHERLOCK's RPA step (see next paragraph) improves sensitivity and resolves detection. 26 When SHERLOCK is modified so that PCR amplification can be skipped, the assay maintains 100% sensitivity and 100% specificity.

Another measure of an assay's performance is its lower limit of detection (LoD). Comparable to PCR, SHERLOCK has an LoD at single copy/ml, attomolar (aM; 10 −18 M) range. 20 fragments. 20 SHERLOCK also detected 16S rRNA sequences differentiating bacterial strains, as well as SNPs differentiating human subjects or ZIKV strains. 20 In a later study, SHERLOCK could again detect ZIKV SNPs and HIV drug-resistant mutations. This time, the researchers started from zero reagents-the crRNAs were designed, Cas13 was purified, and the assay was working within 1 week. 24 This study proved that SHERLOCK is ready for real patient samples. 26 In total, there were 380 clinical samples. 26 The sensitivities and specificities of detection found in all referenced studies were higher than that of traditional RT-PCR tests (see above).

Patchsung et al. 26 also multiplexed detection of RNase contamination with SARS-CoV-2 mRNA on the same lateral flow strip.

The ability to detect RNAse contamination eliminates false negatives from the degradation of input RNA and eliminates false positives from the degradation of the RNA sensor. SHERLOCK will be reliable in the field, even where clean facilities and equipment are not available, and particularly in low-resource environments.

Although SHERLOCK has been thoroughly tested in real-world settings and with COVID-19 cases, the current assay does not have the throughput necessary to significantly improve the lack of testing during The studies presented in this review have applied SHERLOCK and CARMEN to real-world situations and serve as proof-of-concept.

Expanding these field-ready assays to a variety of zoonotic and clinical settings will ultimately show that the assays drastically improve the speed and accuracy of a doctor's diagnosis. CRISPR-Cas13's eventual application as both a nucleic acid detection assay and a therapeutic means will make the system a swiss army knife against disease. All told the CRISPR-Cas system has been greatly enhanced since it was first discovered and used to edit the genome.

The rapid progress in genome technologies has shown that they are the future of medicine.

Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis

COVID-19 diagnosis and management: a comprehensive review

Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape

The impact of case diagnosis coverage and diagnosis delays on the effectiveness of antiviral strategies in mitigating pandemic influenza A/H1N1

MERS coronavirus: diagnostics, epidemiology and transmission

HIV-1 drug resistance and resistance testing

High throughput sequencing and assessing disease risk. Cold Spring Harb Perspect Med

Germinal immunogenetics as a predictive factor for immunotherapy

SNPs affecting the clinical outcomes of regularly used immunosuppressants

Review of clinical next-generation sequencing

Multiplex genome engineering using CRISPR/Cas systems

RNA-guided human genome engineering via Cas9

Delivering CRISPR: a review of the challenges and approaches

CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III

Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

C2c2 is a singlecomponent programmable RNA-guided RNA-targeting CRISPR effector

Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system

Nucleic acid detection with CRISPR-Cas13a/C2c2

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

Room temperature detection of plasma Epstein-Barr virus DNA with CRISPR-Cas13

CRISPR-Cas12a-assisted nucleic acid detection

Field-deployable viral diagnostics using CRISPR-Cas13

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

SHERLOCK: nucleic acid detection with CRISPR nucleases

Detection of SARS-CoV-2 with SHERLOCK one-pot testing

Rapid detection of SARS-CoV-2 with Cas13. medRxiv

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

Massively multiplexed nucleic acid detection with Cas13

The appropriate use of testing for COVID-19

Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)

RNA viruses: a case study of the biology of emerging infectious diseases

Characteristics of microbes most likely to cause pandemics and global catastrophes

RNA editing with CRISPR-Cas13

Programmable inhibition and detection of RNA viruses using Cas13

Development and application of sensitive, specific, and rapid CRISPR-Cas13-based diagnosis

The authors declare that there are no conflict of interests.